Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2002-07-03
2009-10-06
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
Reexamination Certificate
active
07597908
ABSTRACT:
The use of poly(lactide) or poly(lactide-co-glycolide) microparticles with adsorbed antigen is disclosed. The microparticles are useful for enhancing CTL responses to a selected antigen.
REFERENCES:
patent: 4413057 (1983-11-01), Carlo et al.
patent: 4534996 (1985-08-01), Rembaum et al.
patent: 5010183 (1991-04-01), Macfarlane
patent: 5151225 (1992-09-01), Morgan et al.
patent: 5630922 (1997-05-01), Eswarakrishnan et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5660854 (1997-08-01), Haynes et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5714354 (1998-02-01), Arnold et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5827531 (1998-10-01), Morrison et al.
patent: 5830430 (1998-11-01), Unger et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5869103 (1999-02-01), Yeh et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5902565 (1999-05-01), Cox et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6270769 (2001-08-01), Raychaudhuri et al.
patent: 6468982 (2002-10-01), Weiner et al.
patent: 6753015 (2004-06-01), Fang et al.
patent: 6884435 (2005-04-01), O'Hagan et al.
patent: 6977074 (2005-12-01), Kundig et al.
patent: 2003/0049298 (2003-03-01), O'Hagan et al.
patent: 2004/0022814 (2004-02-01), O'Hagan et al.
patent: WO 91/02062 (1991-02-01), None
patent: WO 94/15635 (1994-07-01), None
patent: WO 94/28879 (1994-12-01), None
patent: WO 95/24929 (1995-09-01), None
patent: WO 95/32000 (1995-11-01), None
patent: WO 96/30514 (1996-03-01), None
patent: WO 96/20698 (1996-07-01), None
patent: WO 97/02810 (1997-01-01), None
patent: WO 97/24447 (1997-07-01), None
patent: WO 98/10750 (1998-03-01), None
patent: WO 98/33487 (1998-08-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 01/08636 (2001-02-01), None
Coombes et al. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen.
Coombes et al., Vaccines, vol. 14, No. 15, pp. 1429-1438.
Kang et al. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc. Natl. Acad. Sci. USA., Jul. 1991, vol. 88, pp. 6171-6175.
O'Hagan et al., “Long-term antibody responses in mice following subcutaneous Immunization with ovalbumin entrapped in biodegradable microparticles,” Vaccine 11:965-969, 1993.
Coombes et al., “Single Dose, Polymeric, Microparticle-Based Vaccines: The Influence of Formulation Conditions on the Magnitude and Duration of the Immune REsponse to a Protein Antigen,” Vaccine 14 (15):1429-1438 (1996).
Almeida, Antonio J. et al., “Poly(lactic acid) microspheres as immunological adjuvants for orally delivered cholera toxin B subunit,”Biochemcial Society Transactions(1992) 20, p. 316S.
Almeida, Antonio, J., et al., “Immune Response To Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(L-lactic acid) Microspheres in Rats, Rabbits and Guinea-pigs,”J. Pharm. Pharmacol. 1993, 45: 198-203, pp. 198-203.
Jackson, Raymond J., “Oral Vaccine Models: Multiple Delivery Systems Employing Tetanus Toxoid,”Annals New York Academy of Sciences, 1994, vol. 730, pp. 217-234.
H.O. Alpar et al., Immune Responses to Mucosally Administered Tetanus Toxoid in Biodegradable Micropsheres,Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 21 (1994), pp, 867-868.
Bertling, et al., “Use of Liposomes, Viral Capsids, and Nano-particles as DNA Carriers”,Biotechnology and Applied Bio-chemistry, vol. 13, pp. 390-405 (1991).
Haynes et al.,AIDS Research and Human Retroviruses, vol. 10, Supplement 2, 1994, pp. S42-S45.
P. Moingeon, “Cancer Vaccines,”Vaccine, vol. 19, 2001, pp. 1305-1326.
Steven A. Rosenberg, “Progress in Human Tumour Immunology and Immunotherapy,”Nature, vol. 411, May 17, 2001, pp. 380-384.
Said Dermime et al., “Cancer Vaccines and Immunotherapy,”British Medical Bulletin, vol. 62, 2002, pp. 149-162.
Ian D. Davis et al., “Rational Approaches to Human Cancer Immunotherapy,”Journal of Leukocyte Biology, vol. 73, Jan. 2003, pp. 3-29.
Igor Espinoza-Delgado, “Cancer Vaccines,”The Oncologist, vol. 7 (suppl3), 2002, pp. 20-33.
Phil Gold et al., “Specific Carcinoembryonic Antigens of the Human Digestive System,”Journal of Experimental Medicine, vol. 122, 1965, pp. 467-481.
Xiao-Juan Zhao et al., “GD2Oligosaccharide: Target for Cytotoxic T Lymphocytes,”Journal of Experimental Medicine, vol. 182, Jul. 1995, pp. 67-74.
Phillip O. Livingston et al., “Carbohydrate Vaccines That Induce Antibodies Against Cancer. I. Rationale,”Cancer Immunol. Immunother.. vol. 45, 1997, pp. 1-9.
Pascal Chaux et al., “ Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+T Lymphocytes,”Journal of Experimental Medicine, vol. 189, No. 5 Mar. 1, 1999, pp. 767-777.
Lloyd J. Old et al., “New Paths in Human Cancer Serology,”Journal of Experimental Medicine, vol. 187, No. 8, Apr. 20, 1998, pp. 1163-1167.
Gustav Gaudernack, “T Cell Responses Against MutantRas: A Basis for Novel Cancer Vaccines,”Immunotechnology, vol. 2, 1996, pp. 3-9.
Steven A. Rosenberg, “Cancer Vaccines Based on the Identification of Genes Encoding Cancer Regression Antigens,”Immunology Today, vol. 18, No. 4, Apr. 1997, pp. 175-182.
Joyce Taylor-Papadimitriou et al., “Biology, Biochemistry and Immunology of Carcinoma-Associated Mucins,”Immunology Today, vol. 18, No. 3, Mar. 1997, pp. 105-107.
Steven A. Rosenberg, “A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens,”Immunity, vol. 10, Mar. 1999, pp. 281-287.
Matthias Theobald et al., “Targeting p53 as a General Tumor Antigen,”Proceedings of the National Academy of Sciences USA, vol. 92, Dec. 1995, pp. 11993-11997.
Ugur Sahin et al., “Serological Identification of Human Tumor Antigens,”Current Opinion in Immunology, vol. 9, 1997, pp. 709-716.
Benoit Van den Eyode et al., “New Tumor Antigens Recognized by T Cells,”Current Opinion in Immunology, vol. 7, 1995, pp. 674-681.
Phillip O. Livingston et al., “Carbohydrate Vaccines That Induce Antibodies Against Cancer, 2. Previous Experience and Future Plans,”Cancer Immunol. Immunother., vol. 45, 1997, pp. 10-19.
Rienk Offringa et al., “Design and Evaluation of Antigen-Specific Vaccination Strategies Against Cancer,”Current Opinion in Immunology, vol. 12, 2000, pp. 576-582.
Yunping Luo et al., “A DNA Vaccine Encoding Carcinoembryonic Antigen (CEA) Adsorbed onto Cationic Microparticles and Boosted with GM-CSF Induces T Cell— Mediated Protective Immunity Against Colon Cancer in CEA-Transgenic Mice” Abstract of presentation at the 2002 AACR Annual Meeting on Monday, Apr. 8, 2002, 1 p.
Christine Chavany, et al., “Adsorption of Oligonucleotides onto polyisohexylcyanoacrylate Nanoparticles Protects Them Against Nucleases and Increases Their Cellular Uptake,”Pharmaceutical research, vol. 11, No. 9, 1994, pp. 1370-1378.
Elias Fattal, et al., “Biodegradable Polyalkylcyanocrylate Nanoparticles for the Delivery of Olionucleotides,”Journal of Controlled Release, 53 (1998), pp. 137-143.
Duncan et al., “Poly (Lactide-Co-Glycolide) Microencapsulation of Vaccines for Mucosal Immunization,” Mucosal Vaccine (Academic Press) pp. 159-173 (1996).
Eldridge et al. “Biodegradable and Biocompatible Poly (DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies,” Infect. and Immunity, 1991, 59(9):2978-2986.
Eldrid
Barackman John
Kazzaz Jina
O'Hagan Derek
Ott Gary S.
Van Nest Gary
Bonham David
Le Emily M.
Lee Helen
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Use of microparticles with adsorbed antigen to stimulate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of microparticles with adsorbed antigen to stimulate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of microparticles with adsorbed antigen to stimulate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078731